Here are the 10-K annual reports from MBX Biosciences, Inc. (MBX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBX filings page.
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders using its proprietary Precision Endocrine Peptide (PEP™) platform. The company engineers long-acting peptide prodrugs with extended time-action profiles and low peak-to-trough ratios for less frequent dosing and potentially better tolerability.
Lead program canvuparatide (MBX 2109) targets chronic hypoparathyroidism with once-weekly parathyroid hormone replacement and has shown positive Phase 2 results; a Phase 3 trial is planned for the third quarter of 2026. Obesity candidate MBX 4291, a GLP‑1/GIP co-agonist prodrug, is in a Phase 1 trial and is designed for potential once-monthly dosing.
The company is also advancing imapextide (MBX 1416), a long-acting GLP‑1 receptor antagonist for post-bariatric hypoglycemia, now in a Phase 2a trial with topline results expected in the second quarter of 2026. MBX relies on third-party manufacturers, in-licenses key PEP™ intellectual property from Indiana University entities, and faces typical clinical, regulatory, funding and competitive risks highlighted in extensive risk factor disclosures.